Immunosuppression With Mycophenolate Mofetil and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies or Metastatic Renal Cell Carcinoma - Related Studies

Immunosuppression With Mycophenolate Mofetil and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies or Metastatic Renal Cell Carcinoma

This study is ongoing, but not recruiting participants.

Study NCT00078858. Last updated on November 16, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Graft Versus Host Disease
		Kidney Cancer
		Leukemia
		Lymphoma
		Myelodysplastic Syndromes

2	Additional conditions recognized in this trial
		Carcinoma
		Carcinoma, Renal Cell
		Graft vs Host Disease
		Hematologic Neoplasms
		Kidney Neoplasms
		Multiple Myeloma
		Myelodysplastic-Myeloproliferative Diseases
		Myeloproliferative Disorders
		Neoplasms, Plasma Cell
		Preleukemia
		Syndrome

3	More general conditions related to this trial
		Adenocarcinoma
		Blood Protein Disorders
		Bone Marrow Diseases
		Cardiovascular Diseases
		Disease
		Hematologic Diseases
		Hemorrhagic Disorders
		Hemostatic Disorders
		Immune System Diseases
		Immunoproliferative Disorders
		Kidney Diseases
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Paraproteinemias
		Pathologic Processes
		Precancerous Conditions
		Urogenital Neoplasms
		Urologic Diseases
		Urologic Neoplasms
		Vascular Diseases

4	Interventions listed in this trial
		cyclosporine
		fludarabine phosphate
		mycophenolate mofetil
		radiation therapy

5	Additional drug interventions recognized in this trial
		Cyclosporins
		Fludarabine
		Fludarabine monophosphate
		Mycophenolic Acid

6	More general drug interventions related to this trial
		Anti-Infective Agents
		Antibiotics, Antineoplastic
		Antifungal Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antirheumatic Agents
		Dermatologic Agents
		Enzyme Inhibitors
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Fred Hutchinson Cancer Research Center
		National Cancer Institute (NCI)